Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-11-20
2007-11-20
Seaman, Margaret D. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
10922678
ABSTRACT:
The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor
REFERENCES:
patent: 5977131 (1999-11-01), Nagel
patent: 6100291 (2000-08-01), Slassi et al.
patent: 6187805 (2001-02-01), Pineiro et al.
patent: 6476034 (2002-11-01), Wang et al.
patent: 6770642 (2004-08-01), Cole et al.
patent: WO00/063203 (2000-10-01), None
patent: WO01/12629 (2001-02-01), None
Adell, et al, “strategies for producing faster acting antidepressants”, Drug Discovery Today, 10 (8), Apr. 2005, pp. 578-585.
Schechter, et al., “the potential utility of 5HT1a . . . ”Curr. Pharm. Des., 2002, 8(2), abstract.
Kwon, et al., “List of drugs in development . . . ”Neurodegenerative Dis., 2004; 1:113-152.
Matsumoto, et al., “5HT2a and muscarinic receptors . . . ”, Neuroscience Letters, 379 (2005), 164-168.
STN results.
Russel et al., N-Arylsulfonylindole Derivatives as Serotonin 5-HT6 Receptor Lignads, J. Med. Chem.. 44:3881-3895 (2001).
Hayes & Adaikan, The Effects of 5HT1 agonists on Erection in Rats in vivo and Rabbit Corpus Cavernosum in vitro, International Journal of Impotence Research, 14:205-2112 (2002).
Mitchell et al., 5-HT6 Receptors: A Novel Target for Cognitive Enhancement, Pharm. & Ther. 108:320-333 (2005).
Slassi et al, Recent Progress in 5-HT6 Receptor Antagonists for the Treatment of CNS Disease, Expert Opinion on Therapeutic Patents, 12(4):513-527 (2002).
J. Mérour et al, Reactions of Substituted 2,3-Dihydro-1H-indol-3-ones and Pyrrolo[2,3-b]pyridin-3-ones with Wittig and Horner-Emmons Reagents: Synthesis of 7-Azatryptamine, Tetrahedron 57 (2001) 1995-2002.
D. Mazéas et al, Synthesis of New Melatoninergic Ligands Including Azaindole Moiety, Heterocycles 50 (1999) 1065-1080.
M. Hichour et al, Synthesisi of 4,5-Disubstituted-2-piperidinones from 4-Piperidinones, Heterocyclic Communications 4 (1998) 71-76.
Meneses, A., Behavioural Brain Research 118 (2001), 107-110.
Slassi, A., Isaac, M., and O'Brien, A., Expert Opinion Therapeutic Patents (2002) 12(4), 513-527.
Miguel-Hidalgo, J. J., Current Opinion in Investigational Drugs (2001) 2(1), 118-122.
WO 01/12629.
Bernotas Ronald Charles
Cole Derek Cecil
Lennox William Joseph
Lences Barbara L.
Wyeth
LandOfFree
Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3820899